globenewswire.com/news-release/2…

globenewswire.com/en/news-releas…

benzinga.com/pressreleases/…

$OTLC new 52 week high Oncotelic Therapeutics, Inc. Held at DTC 115,937,927 03/05/2025

Four more years of this nonsense! 'Failed group of incompetents': Trump uses plight of stuck astronauts to shame Biden

benzinga.com/partner/biotec…

Go to discord if you want to access the latest information on Oncotelic. discord.gg/tFufJy9N

biospace.com/press-releases…

Just dropped: a user-friendly blog and a third-party podcast now live in our Content Hub on Discord. You can also interact with the chatbot about Vuong’s presentation World Cancer Research (SWCR 2025) in Kyoto. Join the conversation: discord.gg/jz6Q7G2SBQ

Explore the highlights from Dr. Vuong Trieu's recent presentation at the 2025 Symposium on World Cancer Research, covering OT-101’s potential to target TGF-β2 in pancreatic cancer and glioblastoma. Read the full insights here: medium.com/@blog_19647/pr…

morningstar.com/news/globe-new…

💬You are invited to explore the impact of TGFB2 Methylation in GBM on Discord at discord.com/invite/gWrUz3P… for the paper available online at👉 mdpi.com/2072-6694/17/7… 👥by Sanjive Qazi et al. Oncotelic Therapeutics (OTCQB: OTLC)

linkedin.com/posts/towards-…

Oncotelic Therapeutics Showcases Robust Pipeline and Founder’s Broad Intellectual Property Contributions to Biopharma Industry, highlighting multibillion-dollar drug discoveries and advancing novel oncology and immunotherapy assets. $OTLC otcmarkets.com/stock/OTLC/new…

Dr. Vuong Trieu, Developer of Novel Oncology and Immunotherapy Assets, Leads Oncotelic Therapeutics’ Commitment to Innovation, Life-Saving Therapies $OTLC otcmarkets.com/stock/OTLC/new…

Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage Pipeline $OTLC oncotelic.com/press-releases/

New Podcast: Dr. Trieu joins BioMedWire to talk biotech, innovation, and the future of oncology. From navigating clinical trials to tackling the toughest challenges in cancer treatment, his insights reveal why this work matters far beyond the lab. $OTLC

Oncotelic Advances to Phase 1 Human Clinical Trials New Injectable Formulation for Treating Breast Cancer $OTLC oncotelic.com/press-releases/

New Podcast: Dr. Trieu joins BioMedWire to discuss Oncotelic’s major update on the latest clinical milestone: the advancement of Sapu-003, a novel IV formulation of everolimus (Afinitor®) built on Oncotelic’s proprietary Deciparticle™ platform. $OTLC oncotelic.com